Compare DexCom, Inc. (DXCM) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs IQIYI Inc - ADR — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while IQIYI Inc - ADR trades at $1.25 (market cap $1.15B). The key difference: DexCom, Inc. is far larger — about 24.4× IQIYI Inc - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| DXCM | IQ | |
|---|---|---|
Market Cap | $28.06B | $1.15B |
Sector | Health | Media |
52-Week High | $89.53 | $2.79 |
52-Week Low | $54.84 | $0.96 |
Enterprise Value | $27.03B | $2.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
IQ (iQIYI) trades at $1.16, up 2.65% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two of the last three quarters. Recent news highlights AI platform growth and leadership changes as potential turnaround catalysts.
The outlook is mixed: analyst consensus leans buy (50%) with price predictions citing upside potential, but profitability challenges and revenue declines pose risks. Investment opportunity hinges on AI-driven content innovation offsetting competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
